{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:17:46Z","timestamp":1780679866790,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA166701"],"award-info":[{"award-number":["R01 CA166701"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA105274"],"award-info":[{"award-number":["R01 CA105274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA195565"],"award-info":[{"award-number":["U01 CA195565"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10549-017-4626-5","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T11:13:56Z","timestamp":1513422836000},"page":"523-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy"],"prefix":"10.1007","volume":"168","author":[{"given":"Marilyn L.","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile A.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janise M.","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles P.","family":"Quesenberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Kushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,16]]},"reference":[{"issue":"23","key":"4626_CR1","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, American Society of Clinical O (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784\u20133796. \n                    https:\/\/doi.org\/10.1200\/jco.2009.26.3756","journal-title":"J Clin Oncol"},{"issue":"3","key":"4626_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509\u2013518. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.1274","journal-title":"J Clin Oncol"},{"issue":"1","key":"4626_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69(1):73\u201382. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2008.07.013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"33","key":"4626_CR4","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1200\/JCO.2006.07.5382","volume":"24","author":"AJ Chien","year":"2006","unstructured":"Chien AJ, Goss PE (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24(33):5305\u20135312. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.07.5382","journal-title":"J Clin Oncol"},{"issue":"10","key":"4626_CR5","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1210\/me.2014-1147","volume":"28","author":"M Liu","year":"2014","unstructured":"Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A, Jenkins GD, Carlson EE, Nakamura Y, Schaid DJ, Chapman JA, Shepherd LE, Ellis MJ, Khosla S, Wang L, Weinshilboum RM (2014) Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol 28(10):1740\u20131751. \n                    https:\/\/doi.org\/10.1210\/me.2014-1147","journal-title":"Mol Endocrinol"},{"issue":"3","key":"4626_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209\u2013219. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1604700","journal-title":"N Engl J Med"},{"issue":"4","key":"4626_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12254-016-0300-6","volume":"9","author":"R Bartsch","year":"2016","unstructured":"Bartsch R, Bergen E (2016) ASCO 2016: highlights in breast cancer. Memo 9(4):211\u2013214. \n                    https:\/\/doi.org\/10.1007\/s12254-016-0300-6","journal-title":"Memo"},{"issue":"10","key":"4626_CR8","doi-asserted-by":"publisher","first-page":"e111477","DOI":"10.1371\/journal.pone.0111477","volume":"9","author":"ML Kwan","year":"2014","unstructured":"Kwan ML, Lo JC, Tang L, Laurent CA, Roh JM, Chandra M, Hahn TE, Hong CC, Sucheston-Campbell L, Hershman DL, Quesenberry CP Jr, Ambrosone CB, Kushi LH, Yao S (2014) Bone health history in breast cancer patients on aromatase inhibitors. PLoS ONE 9(10):e111477. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0111477","journal-title":"PLoS ONE"},{"issue":"3","key":"4626_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10549-016-4068-5","volume":"161","author":"S Yao","year":"2017","unstructured":"Yao S, Zhang Y, Tang L, Roh JM, Laurent CA, Hong CC, Hahn T, Lo JC, Ambrosone CB, Kushi LH, Kwan ML (2017) Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. Breast Cancer Res Treat 161(3):501\u2013513. \n                    https:\/\/doi.org\/10.1007\/s10549-016-4068-5","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"4626_CR10","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1007\/s00198-016-3673-9","volume":"27","author":"JC Lo","year":"2016","unstructured":"Lo JC, Kim S, Chandra M, Ettinger B (2016) Applying ethnic-specific bone mineral density T-scores to Chinese women in the USA. Osteoporos Int 27(12):3477\u20133484. \n                    https:\/\/doi.org\/10.1007\/s00198-016-3673-9","journal-title":"Osteoporos Int"},{"key":"4626_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-499-9","volume-title":"Bone densitometry in clinical practice","author":"S Bonnick","year":"2010","unstructured":"Bonnick S (2010) Bone densitometry in clinical practice. Humana Press, New York. \n                    https:\/\/doi.org\/10.1007\/978-1-60327-499-9"},{"issue":"4","key":"4626_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","volume":"16","author":"JT Schousboe","year":"2013","unstructured":"Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 international society for clinical densitometry position development conference on bone densitometry. J Clin Densitom 16(4):455\u2013466. \n                    https:\/\/doi.org\/10.1016\/j.jocd.2013.08.004","journal-title":"J Clin Densitom"},{"issue":"12","key":"4626_CR13","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","volume":"22","author":"P Hadji","year":"2011","unstructured":"Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22(12):2546\u20132555. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdr017","journal-title":"Ann Oncol"},{"key":"4626_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2017.08.008","author":"O Bruyere","year":"2017","unstructured":"Bruyere O, Bergmann P, Cavalier E, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Body JJ (2017) Skeletal health in breast cancer survivors. Maturitas. \n                    https:\/\/doi.org\/10.1016\/j.maturitas.2017.08.008","journal-title":"Maturitas"},{"issue":"5","key":"4626_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/aje\/kwf049","volume":"156","author":"KE Bainbridge","year":"2002","unstructured":"Bainbridge KE, Sowers MF, Crutchfield M, Lin X, Jannausch M, Harlow SD (2002) Natural history of bone loss over 6\u00a0years among premenopausal and early postmenopausal women. Am J Epidemiol 156(5):410\u2013417","journal-title":"Am J Epidemiol"},{"issue":"9","key":"4626_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlbock M, Jakesz R, Austrian B, Colorectal Cancer Study G (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840\u2013849. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(08)70204-3","journal-title":"Lancet Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4626-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:04:43Z","timestamp":1589720683000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4626-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,16]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4626"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4626-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,16]]},"assertion":[{"value":"6 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Lo or a household member has received research funding from Amgen, Sanofi, Novartis, GlaxoSmithKline, or AstraZeneca unrelated to this study. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}